Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00445003 · ClinicalTrials.gov registry record · Phase 3
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
A Phase 3 study, sponsored by Jaeb Center for Health Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 333
- Enrollment target
NCT00445003 is a Phase 3 study that has completed, run by Jaeb Center for Health Research. The registered enrollment target is 333 participants.
The verdict
NCT00445003, a Phase 3 study, has completed, sponsored by Jaeb Center for Health Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 333 participants
- Enrollment target
Study Summary
The purpose of the study is to find out if treatment with an intravitreal injection of triamcinolone or an intravitreal injection of ranibizumab can prevent loss of vision caused by panretinal photocoagulation treatment. At the present time, it is not known whether intravitreal steroid or anti-vascular endothelial growth factor (anti-VEGF) injections are beneficial in preventing vision loss after panretinal photocoagulation (PRP) treatment. It is possible that one or both of the types of injections will prevent vision loss after PRP treatment. However, it is not known whether the benefits of the injections will outweigh the risks. It is possible that because of side effects, the injections may not be as good as laser alone in treating the diabetic retinopathy.
Interventions
- DRUG Triamcinolone Acetonide
- DRUG Ranibizumab
- BEHAVIORAL Sham injection
- PROCEDURE Focal/grid laser
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 333 participants |
| Start Date | 2007-03 |
| Est. Completion | 2010-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00445003
The ClinicalTrials.gov registry entry for NCT00445003 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 333 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jaeb Center for Health Research, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Triamcinolone Acetonide is the first listed.
NCT00445003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00445003 about?
NCT00445003 is a clinical study titled "Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy". The purpose of the study is to find out if treatment with an intravitreal injection of triamcinolone or an intravitreal injection of ranibizumab can prevent loss of vision caused by panretinal photocoagulation treatment. At the present time, it is not known whether intravitreal steroid or anti-vascu...
What is the current status of trial NCT00445003?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 333 participants. The study started on 2007-03. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00445003?
The interventions under investigation include: Triamcinolone Acetonide (DRUG), Ranibizumab (DRUG), Sham injection (BEHAVIORAL), Focal/grid laser (PROCEDURE).
Who is sponsoring clinical trial NCT00445003?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.